Boris C Bastian

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin
    David C Whiteman
    Cancer Control Group, Queensland Institute of Medical Research, Brisbane, QLD, Australia
    Pigment Cell Melanoma Res 24:879-97. 2011
  2. ncbi KIT as a therapeutic target in metastatic melanoma
    Richard D Carvajal
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    JAMA 305:2327-34. 2011
  3. ncbi Germline mutations in BAP1 predispose to melanocytic tumors
    Thomas Wiesner
    Department of Dermatology, Medical University of Graz, Graz, Austria
    Nat Genet 43:1018-21. 2011

Collaborators

  • Richard D Carvajal
  • Thomas Wiesner
  • David C Whiteman
  • Alex E Lash
  • Klaus G Griewank
  • Kenneth Offit
  • Nicholas D Socci
  • Bartosz Chmielowski
  • Shea Loy
  • Gary K Schwartz
  • Swapna Vemula
  • Paul B Chapman
  • Lauren Cane
  • Jose Lutzky
  • Lorenzo Cerroni
  • Ingrid Wolf
  • William J Pavan
  • Klaus J Busam
  • Anna C Pavlick
  • Katherine S Panageas
  • Michael R Speicher
  • Naoko Takebe
  • Gabriele Palmedo
  • Ruth Ann Roman
  • Jurgen C Becker
  • Christian Windpassinger
  • Heinz Kutzner
  • Peter Ulz
  • Isabella Fried
  • Rajmohan Murali
  • Anne Fusco
  • Arno Rutten
  • Werner Wackernagel
  • Jerrold Teitcher
  • Arthur Ott
  • Jedd D Wolchok
  • Agnes Viale
  • David Abramson
  • Cristina R Antonescu
  • Mono Pirun
  • Nancy Bouvier
  • Anna C Obenauf

Detail Information

Publications3

  1. ncbi The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin
    David C Whiteman
    Cancer Control Group, Queensland Institute of Medical Research, Brisbane, QLD, Australia
    Pigment Cell Melanoma Res 24:879-97. 2011
    ..We integrate the evidence from these separate trajectories to catalog the emerging major categories of melanomas and conclude with important unanswered questions relating to the development of melanoma and its cells of origin...
  2. ncbi KIT as a therapeutic target in metastatic melanoma
    Richard D Carvajal
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    JAMA 305:2327-34. 2011
    ..We explored the effects of KIT inhibition using imatinib mesylate in this molecular subset of disease...
  3. ncbi Germline mutations in BAP1 predispose to melanocytic tumors
    Thomas Wiesner
    Department of Dermatology, Medical University of Graz, Graz, Austria
    Nat Genet 43:1018-21. 2011
    ..These findings suggest that loss of BAP1 is associated with a clinically and morphologically distinct type of melanocytic neoplasm...